BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China

DHCG And Altruist Biologics Partner To Accelerate Global Biologics Development Through China Manufacturing Expertise

Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, and Altruist...

June 05, 2026 | News

Correctseq Reports 15 Month Crisis Free Outcome in First Sickle Cell Disease Patient Treated With CS 206

CorrectSequence Therapeutics Co., Ltd. (Correctseq), a clinical-stage biotechnology company pioneering transformer Base Editing (tBE) technology for ...

June 04, 2026 | News

Travere Secures Global Rights to Civorebrutinib in $1.14 Billion Kidney Disease Partnership with Everest Medicines

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience in immun...

June 04, 2026 | News

Innovation Powerhouse or Inflated Bubble? Reading China’s First-in-Class Boom

A decade ago, the phrase “Chinese first-in-class drug” would have drawn a raised eyebrow in any Western boardroom. China made generics, copied ...

June 02, 2026 | Analysis | By arcilla.fran@biopharmaapac.com

XtalPi Earns Second Milestone Payment As AI Drug Discovery Alliance With DoveTree Gains Momentum

XtalPi (2228.HK), an AI- and robotics- powered drug discovery platform, announced that its strategic collaboration with innovative biopharmaceutical c...

June 02, 2026 | News

Lynk Pharmaceuticals Advances LNK01004 Into Phase II Trials For Vitiligo And Chronic Hand Eczema

Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, ...

June 02, 2026 | News

ImmVira Reports 100% Complete Response Rate With MVR T3011 In BCG Unresponsive Bladder Cancer

ImmVira Group announced that preliminary Phase IIa clinical data for MVR-T3011, its lead oncolytic immunotherapy candidate, was presented at the 2026 Ameri...

June 02, 2026 | News

Lilly Secures Global Rights To Hanmi's Sonefpeglutide In Potential $1.26 Billion Deal

Lilly licenses Hanmi's sonefpeglutide (LAPSGLP-2 analog) for multiple indications Hanmi Pharm. Co., Ltd. ("Hanmi") announced that they have entered i...

June 02, 2026 | News

China Developed Anaesthetic Cipepofol Secures US FDA Approval, Marking Global Breakthrough

Cipepofol (CYPSEDO) Injection (hereinafter "Cipepofol"), a Class 1 innovative intravenous anesthetic independently developed by Haisco Pharmaceutical ...

June 02, 2026 | News

Pfizer And Innovent Biologics Forge Global Oncology Alliance Covering 12 Cancer Programs

Pfizer Inc. and Innovent Biologics, Inc. announced the companies have entered into a strategic global licensing and collaboration agreement for the r...

June 01, 2026 | News

Dizal Secures Priority Review In China For ZEGFROVY In First Line EGFR Exon20ins NSCLC

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced...

May 29, 2026 | News

Antengene Receives CDE Endorsement For Pivotal Phase III Study Of CLDN18.2 ADC In Gastric Cancer

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, d...

May 29, 2026 | News

Ribo Submits Phase 2 CTA To EMA For siRNA Therapy Targeting Coronary Artery Disease

Suzhou Ribo Life Science (stock code 06938.HK) and Ribocure Pharmaceuticals (together "Ribo") announce the submission of Phase 2 Clinical Trial Application...

May 29, 2026 | News

Nuance Pharma Secures NMPA Clearance For Pivotal Actair® Allergy Trial In China

NMPA Approval Marks Key Milestone in Advancing House Dust Mite Allergy Immunotherapy to Chinese Patients Nuance Pharma announced that the National Medical...

May 25, 2026 | News

Stay Connected